Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Income from Continuing Operations (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Income from Continuing Operations for 14 consecutive years, with 18899000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 34.14% to 18899000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 67046000.0 through Dec 2025, down 41.73% year-over-year, with the annual reading at 51418000.0 for FY2025, 75.12% down from the prior year.
  • Income from Continuing Operations hit 18899000.0 in Q4 2025 for Vistagen Therapeutics, up from 19417000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 6211000.0 in Q1 2021 to a low of 19776300.0 in Q2 2022.
  • Historically, Income from Continuing Operations has averaged 12370585.0 across 5 years, with a median of 12511000.0 in 2021.
  • Biggest five-year swings in Income from Continuing Operations: crashed 287.99% in 2021 and later surged 65.09% in 2023.
  • Year by year, Income from Continuing Operations stood at 10534000.0 in 2021, then increased by 7.34% to 9761200.0 in 2022, then skyrocketed by 34.95% to 6350000.0 in 2023, then crashed by 121.87% to 14089000.0 in 2024, then plummeted by 34.14% to 18899000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for VTGN at 18899000.0 in Q4 2025, 19417000.0 in Q3 2025, and 15095000.0 in Q2 2025.